Are the tides turning on Wall Street? Stocks fell for a third consecutive session, as investors abandoned the tech heavyweights that have been …
Paratek Pharmaceuticals (PRTK) is preparing to launch its drug NUZYRA, following FDA approval granted on October 2nd. The medication treats both community-acquired bacterial …
A Peek Into Today’s Volatile Biotech Stocks
Paratek Pharmaceuticals Inc (NASDAQ:PRTK) shares rose by nearly 31% after the microcap acne medicine maker announced a positive top-line Phase 3 data readout …
Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) is the big winner today – largely thanks to optimism surrounding the company’s cancer drug candidate, CYC065. The company just …
Paratek Pharmaceuticals Inc (NASDAQ:PRTK) shares are rising 11% today after the biotech firm and its collaborator Allergan posted a successful Phase 3 data …
Cantor analyst Chiara Russo is liking the odds for Paratek Pharmaceuticals Inc (NASDAQ:PRTK) after Cempra Inc (NASDAQ:CEMP) received a Complete Response Letter (CRL) …
